The Journal of Urology Vol. 210 (2023): November

Most Comprehensive and Affordable Self-study CME Product!

Make the most of your Journal of Urology® Subscription

Developed by a team of educators, academicians, and clinicians, this valuable home study activity will enhance your knowledge of urology and improve performance as well as patient care at your convenience. For just $2.50 per credit, the Home Study program is designed to provide urologists and residents affordable access to the most recent developments and techniques in urology while reading The Journal®.

Target Audience

  • Practicing Urologists
  • American Board of Urology (ABU) candidates
  • Residents

Learning Objectives

After completing each lesson, the participants will be able to:

  1. Assess their knowledge of urology
  2. Demonstrate an increased knowledge base of urology
  3. Apply the increased knowledge to improve quality of patient care
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
11/01/2023
Course expires: 
11/30/2026
Rating: 
0

Education Council Disclosures

PDF icon Education Council Disclosures_0.pdf

COI Work Group Disclosures

PDF icon COI Review Work Group Disclosures_2.pdf

AUA Staff have nothing to disclose.

All relevant financial disclosures have been mitigated.

Author(s)

Ashish Kamat, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Janssen Pharmaceutical ;.
has a financial relationship (Consultant or Advisor (Oncology)) with Asieris;.
has a financial relationship (Consultant or Advisor (Oncology)) with Cepheid;.
has a financial relationship (Consultant or Advisor (Oncology)) with Photocure;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Heat Biologics;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Sessen Bio;.
has a financial relationship (Consultant or Advisor (Oncology)) with Roche;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Medac;.
has a financial relationship (Consultant or Advisor (Oncology)) with Biological Dynamics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Theralase;.
has a financial relationship (Consultant or Advisor (Oncology)) with Biological Dynamics;.
has a financial relationship (Consultant or Advisor (Oncology)) with MDxHealth;.
has a financial relationship (Consultant or Advisor (Oncology)) with Roviant;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astra Zeneca;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with FKD;.
has a financial relationship (Consultant or Advisor (Oncology)) with Fergene;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Asieris;.
has a financial relationship (Consultant or Advisor (Oncology)) with TMC Innovation;.
has a financial relationship (Consultant or Advisor (Oncology)) with Seattle Genetics;.
has a financial relationship (Consultant or Advisor (Oncology)) with BMS;.
has a financial relationship (Consultant or Advisor (Oncology)) with BioClin Therapeutics;.
has a financial relationship (Scientific Study or Trial (Oncology)) with FerGene;.
has a financial relationship (Leadership Position (Specialty Not Specified)) with IBCG;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Janssen (+Taris);.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with US Biotest;.
has a financial relationship (Consultant or Advisor (Oncology)) with Ferring;.
has a financial relationship (Consultant or Advisor (Oncology)) with Incyte DSMB;.
has a financial relationship (Consultant or Advisor (Oncology)) with ProTara;.
has a financial relationship (Consultant or Advisor (Oncology)) with Abbott Molecular;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.
has a financial relationship (Scientific Study or Trial (General Urology)) with Adolor;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Imagin;.
has a financial relationship (Consultant or Advisor (Oncology)) with Engene;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Arquer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Urogen;.

Deepak Pruthi, MD

has no relevant financial relationships to disclose at this time.

Udit Singhal, MD

has no relevant financial relationships to disclose at this time.

Landon Trost, MD

has a financial relationship (Other) with PathRight Medical;.
Editor(s)

D. Robert Siemens, MD

has no relevant financial relationships to disclose at this time.

Estimated time to complete each lesson: 2.0 hours.

Method of participation in the learning process: Two volumes of The Journal of Urology® are published annually. Each volume is comprised of 6 issues. Five clinically relevant articles are selected by the editor to be offered for CME in each issue of The Journal. For CME credit, the participant must be enrolled in the home study course for the year, read the educational material provided, pass the corresponding online posttest with at least 80% accuracy, submit the online evaluation and claim CME. Please go to: AUAnet.org/JU23. Each issue is designated for a maximum of 2.0 AMA PRA Category 1 Credits™.

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to offlabel or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclosures: A complete list of disclosures can be found at AUAnet.org/JU23Disclosures. All relevant financial disclosures from the JU Editorial Board and authors have been mitigated.

Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA. Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Release Date: November, 2023
Expiration Date: November, 2026 

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.

Accessing your educational material:

Your JU Home Study materials are always available to you via the Quick Links Tab.

  1. Login with your AUA User Name and password.
  2. Hover over Quick Links at the top of page; select JU Home Study.
  3. Select The Journal of Urology® Volumes 209/210 Home Study Course (2023).*
  4. Click "Take Course" to access the content.

* Please note: Under Quick Links, the pricing will still show even if you have already purchased.